Peptide Semaglutide B6/BPC-157 is a compounded therapeutic combination of three unique agents: Semaglutide a GLP-1 receptor agonist that was initially developed to manage type 2 diabetes, but is now used for weight loss, is gaining attention
Compared with dulaglutide 0.75 mg, statistically significant differences in fasting insulin levels were detected in all tirzepatide groups and in fasting C-peptide levels in the tirzepatide 15 mg group as early as week 12, with levels continuing to decline in all three tirzepatide groups through week 52 (Fig
A systematic review from the Hunter Medical Research Institute (HMRI) found that while the medications are effective for weight loss, many clinical trials fail to track changes in diet or whether patients are still getting enough essential nutrients
Notably, weight loss had not completely plateaued by 48 weeks, suggesting longer treatment might lead to even greater reductions
these have done WONDERS
But it also means you need to continuously consume them to avoid becoming deficient